Literature DB >> 1640193

Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis.

S Ljunghall1, A G Johansson, P Burman, O Kämpe, E Lindh, F A Karlsson.   

Abstract

Experimental studies in vitro indicate that insulin-like growth factor 1 (IGF-1) could be of importance for normal bone growth and remodelling, but the clinical relevance of these observations is unknown. In 12 consecutive young to middle-aged male patients (mean age (+/- SD) 46 +/- 8 years, range 30-57 years) with symptomatic idiopathic osteoporosis, the plasma concentrations of IGF-1 were significantly lower than in healthy subjects (0.51 +/- 0.25 vs. 0.73 +/- 0.23 U ml-1; P less than 0.01). The bone mineral densities in the spine, the femoral neck, and the forearm were significantly different between patients and control subjects. There were positive correlations between the plasma IGF-1 concentrations and the bone densities of the spine and the forearm. Three of the patients received a 5-d course of human recombinant growth hormone (GH). During this short period significant increases in plasma IGF-1 levels and in biochemical indices of bone turnover (serum bone-specific alkaline phosphatase, urinary calcium excretion) were recorded. These observations indicate that circulating IGF-1 could have an important role in maintaining bone mass, and suggest that impairment of IGF-1 production is involved in the pathogenesis of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640193     DOI: 10.1111/j.1365-2796.1992.tb00550.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  22 in total

1.  Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.

Authors:  I Kanazawa; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover.

Authors:  A Gürlek; O Gedik
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 3.  Male osteoporosis: new trends in diagnosis and therapy.

Authors:  Hosam K Kamel
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Premenopausal women with idiopathic low-trauma fractures and/or low bone mineral density.

Authors:  A Cohen; R R Recker; J Lappe; D W Dempster; S Cremers; D J McMahon; E M Stein; J Fleischer; C J Rosen; H Rogers; R B Staron; J Lemaster; E Shane
Journal:  Osteoporos Int       Date:  2011-03-02       Impact factor: 4.507

5.  Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: the Rancho Bernardo Study.

Authors:  Simerjot K Jassal; Denise von Muhlen; Elizabeth Barrett-Connor; Clifford J Rosen
Journal:  Osteoporos Int       Date:  2005-08-09       Impact factor: 4.507

6.  Role of insulin-like growth factor-I in primary osteoporosis: a correlative study.

Authors:  L Calò; R Castrignano; P A Davis; G Carraro; E Pagnin; S Giannini; A Semplicini; A D'Angelo
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

7.  IGF-1 Receptor Expression on Circulating Osteoblast Progenitor Cells Predicts Tissue-Based Bone Formation Rate and Response to Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.

Authors:  Adi Cohen; Stavroula Kousteni; Brygida Bisikirska; Jayesh G Shah; J Sanil Manavalan; Robert R Recker; Joan Lappe; David W Dempster; Hua Zhou; Donald J McMahon; Mariana Bucovsky; Mafo Kamanda-Kosseh; Julie Stubby; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2017-03-23       Impact factor: 6.741

8.  MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease.

Authors:  Rebecca Mitchell; Jill McDermid; Mang M Ma; Constance L Chik
Journal:  World J Hepatol       Date:  2011-06-27

Review 9.  Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis.

Authors:  Maya Barake; Asma Arabi; Nancy Nakhoul; Ghada El-Hajj Fuleihan; Sarah El Ghandour; Anne Klibanski; Nicholas A Tritos
Journal:  Endocrine       Date:  2017-10-13       Impact factor: 3.633

Review 10.  Current and potential future drug treatments for osteoporosis.

Authors:  S Patel
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.